Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H2NVAC + trastuzumab emtansine
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
H2NVAC + trastuzumab emtansine is an investigational combination therapy for HER2-positive breast cancer. - **H2NVAC** is a multi-epitope HER2 peptide vaccine designed to stimulate the immune system to recognize and attack HER2-expressing tumor cells. - **Trastuzumab emtansine (T-DM1)** is an antibody-drug conjugate that combines the anti-HER2 monoclonal antibody trastuzumab with the cytotoxic agent DM1 (emtansine), targeting and killing HER2-overexpressing cancer cells by delivering chemotherapy directly into them[1][3][7]. This combination aims to enhance antitumor activity by both direct cytotoxicity (via T-DM1) and immune-mediated mechanisms (via vaccination with H2NVAC). The regimen has shown a favorable safety profile in early-phase clinical trials, with mostly mild adverse events such as injection site reactions and fatigue[1].
- Other names
- H2NVAC + T-DM1H2NVAC plus trastuzumab emtansineH-2NVAC plus trastuzumab emtansineH 2NVAC plus trastuzumab emtansineH2NVAC plus KadcylaH-2NVAC plus KadcylaH 2NVAC plus Kadcyla
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on H2NVAC + trastuzumab emtansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H2NVAC + trastuzumab emtansine.